Antibody-Mediated Rejection (AMR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Antibody-mediated rejection (AMR) is the leading reason for late allograft loss after kidney transplantation. The classification comprises three diagnostic categories for AMR: active AMR, chronic active AMR, and chronic (inactive) AMR. Donor-specific antibodies represent an independent risk factor for AMR and subsequent graft loss. Monitoring AMR treatment responses entails assessing changes in serum creatinine, proteinuria, donor-specific antibodies (DSA) levels, and histopathological findings and exploring potential new approaches. Despite this, there are currently no FDA-approved treatments tailored explicitly for AMR in kidney transplant recipients. Present treatment strategies are based on understanding the pathophysiology of AMR. These approaches often consist of a combination of interventions such as antibody removal, proteasome inhibitors, glucocorticoids, intravenous immunoglobulins (IVIg), anti-CD20 antibodies, and complement blockade.

Thelansis’s “Antibody-Mediated Rejection (AMR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Antibody-Mediated Rejection (AMR) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Antibody-Mediated Rejection (AMR) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Antibody-Mediated Rejection (AMR) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Antibody-Mediated Rejection (AMR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033